DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05360147

CompletedPhase 3

Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Changes in cognitive function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05360147
Org study IDLICD study

Timeline

Milestones

Study start2021-01-20actual
Primary completion2021-04-20actual
Study completion2021-05-10actual
Study first posted2022-05-04actual
Last update posted2022-05-04actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients with Type 2 Diabetes Mellitus

Exclusion criteria

•T2DM with acute diabetic complications;
•type 1 diabetes;
•other diseases affecting cognitive function (e.g., congenital dementia, brain trauma, epilepsy, severe hypoglycemic coma, cerebrovascular disease, ischemic heart disease, renal dysfunction);
•alcohol abuse, mental illness, and psychoactive substance abuse;
•history of thyroid disease;
•any surgical or medical conditions that could significantly influence the absorption, distribution, metabolism, or excretion of interventional drugs;
•unwillingness to provide informed consent.

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
7
Weight & body composition
2
Glycemic / diabetes
2
Cardiometabolic biomarkers
2
Other clinical outcomes
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint/low confidence

Changes of metabolic parameters from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Changes in cognitive function from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, improvement

Other (unclassified)

7 endpoints
Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks

Time frame:0 week, 12 week

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.